Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 13/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12362770 | 0.93 | PDK2 (0.56) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL31464140 | 0.93 | PDK2 (0.56) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL26050380 | 0.93 | PDK2 (0.56) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL26050409 | 0.93 | PDK2 (0.56) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL26058319 | 0.91 | PDK2 (0.48) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL26050362 | 0.88 | PDK2 (0.41) | PDK2LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL24257893 | 0.88 | PDK2 (0.40) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL22151245 | 0.87 | PDK2 (0.51) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL30865781 | 0.87 | PDK2 (0.59) | PDK2CYP1A2PGR | |
| SCHEMBL24665388 | 0.87 | PDK2 (0.59) | PDK2CYP1A2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271989-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271989-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271989-A1 | METAL COMPLEXES | AP3M1, AP1M1, AP2M1 | PDK2 1385/4885KDM4E 3576/4885MEN1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.